

Research Output Journal of Engineering and Scientific Research 3(3): 23-27, 2024

ROJESR Publications Online ISSN: 1115-9790

https://rojournals.org/roj-engineering-and-scientific-research/ Print ISSN: 1115-6155

Engineering Personalized Medicine: Customizing Treatments

Abdullahi Abdirahim Bashiir

Faculty of Engineering Kampala International University Uganda

ABSTRACT

Personalized medicine represents a transformative approach in healthcare, emphasizing customized treatments based on individual genetic, environmental, and lifestyle factors. As advances in genomics, bioinformatics, and digital health tools continue, personalized medicine enables tailored treatment plans, improving patient outcomes while minimizing adverse effects. This paper examines the evolution of personalized medicine, examining key technologies such as gene sequencing, data analytics, and machine learning, which drive precision in clinical applications. We discuss the potential and challenges associated with implementing personalized medicine, including ethical considerations around data privacy, regulatory barriers, and socio-economic disparities. Through real-world case studies in oncology and pharmacogenomics, we highlight successes and limitations, underscoring the importance of interdisciplinary collaboration. The future of personalized medicine promises further integration with AI, creating a proactive healthcare framework but necessitates careful ethical and regulatory alignment.

Keywords: Personalized medicine, genomics, biomarkers, pharmacogenomics, data analytics, artificial intelligence.

INTRODUCTION

Personalized medicine is a healthcare approach that customizes patient treatments, especially medical therapies, to individual patient characteristics. Driven by the patient lifestyle, environment, and the most relevant factor, the patient's genetic makeup, personalized medicine introduces precision in planning and executing medical interventions based on certain patient-specific data. Personalizing medicine on the patient's genetic and molecular data falls under genomics, an umbrella term and diagnostic tool that consists of genomics and other subfields of genetics. The treatment relies mainly on the most popular genomics-related term known as the "biomarker," an indicator for normal biological or disease processes, or in some cases in patients receiving certain treatments; it can provide much information regarding the patient's response to the treatment [1, 2]. Personalized medicine defines an individual patient and moves away from the conventional 'one-size-fits-all' method of treatment. The study and development of personalized medicine aim to design treatments that are best positioned to treat the characteristics of individual patients. The application of personalized medicine often results in improved patient outcomes, enabling more efficient drug approval and medical care. By improving the use of findings that personalize care, the objective of personalized medicine will benefit patients. Additionally, personalized medicine is a promising method for engaging and empowering individuals to play a greater role in managing their health. Large-scale computational resources and a detailed analysis of big healthcare data have laid the foundation for the creation of personalized medicine. This discipline is associated with the use of big data to understand a patient's genetic background, pharmacy, demographics, socioeconomic status, housing, and medical history. In this context, with the collection and comprehensive protection of patient data,

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

advanced analysis algorithms should be able to provide uncertainty with a high degree of specificity. In addition, genomic data now include but are not limited to large bodies of biomedical literature based on cell annotations and biological pathways, and related algorithms built to analyze data within this large purview to address personalized healthcare issues. Taken together, before this presentation, the above-described future attempt will be pursued in two parts: first, how the evolution of personalized medicine into clinical practice reflected the primary objectives of medical care; and second, how two main technologies influenced the emergence of personalized medicine. These are subfields of data analytics, i.e., data interpretation and systems modeling, namely, complex disease/susceptibility interaction inference. Therefore, at present, the narrow focus of the definition of personalized medicine is to align patients according to changes in their genetic background; over time, as data and research become more accessible, treatment can be implemented in a variety of ways. While still in the realm of data analytics, these additional opportunities and applications, as well as the accompanying technologies, clinical applications, and final data, are significant areas for this and further research [3, 4].

Technological Advances in Personalized Medicine

In the last decade, technological advances have brought breakthroughs in personalized medicine, which refers to a healthcare strategy tailored to individual patients. These advances have been enabled by precision instrumentation, rapid gene sequencing that costs 3 billion dollars per genome to around 1,000 dollars today, computational bioinformatics that can decode the function of our genomes to predict the activity of drug-metabolizing enzymes and drug targets, and digital health tools that can track patient outcomes in real-time. As a result, personalized medicine has advanced to stem cell and DNA-based gene editing to cure genetic diseases and resize drug dosages based on liquid biopsies measuring drug-tumor interactions. Precision data analytics are deeply needed to merge genetic and clinical data to the benefit of countless patients today and tomorrow [5, 6]. Personalized medicine has a profound impact on patients at several stages of healthcare based on the subfields of disease prevention, diagnosis, and treatment planning: in precision medication, doctors prescribe the necessary biological tests that take into account patient inheritance in their choice of the best pharmacotherapy and the right dosage, with complete absence or minimization of adverse effects. Disease prevention includes a long subfield of research in multiomics for disease diagnosis and classification, pharmacotherapy, and interventions; it includes the fast-growing digital health in predicting and preventing the expanding Regional Panel for testing key patient genes for responses to one fixed antidepressant dosage with average CYP2D6 metabolism groups being detected, and corresponding SSRIs-related drug alerts in patients' electronic charts. Also integrated into treatment planning are machine-learning models for predicting disease severity and evolution by incorporating multiple types of data. Recently, technological advances have merged genetics and computer science into personalized medicine to predict disease past nowcasting and forecasting for personalized treatment before illness onset. Challenging diseases - mental health and psychiatry: patients needed antipsychotic increases post factum from genomic charts as ranked in 2018. In the next years, the digital or electronic health records pharmacogenomics guided augmentation using CYP450s heart mirroring having an antipsychotic blood concentration of 4–18 nM/L into genomics recommend dosages in large antipsychotic plasma concentration gene groups sustaining personalized therapy for patients with antipsychotic metabolic slow-fast versus moderate metabolism called ultratyrosinemia; that is resistant to high conspecified standards that are related to severe symptoms and better outcomes in the world. EHR digital health provides guidelines on the right next best-matching antipsychotic at the right dosage to genomically assess and predict, helping the doctor quickly select the next best genomically unique antipsychotic based on blood concentration [7, 8].

Challenges and Ethical Considerations

One major challenge is data privacy and informed consent. Although most patients are interested in personalized medicine, they do not understand the processes surrounding genetic testing or data sharing, nor are they fully aware of potential adverse events or possible treatment effects. Ethical concerns go beyond informed consent to include patient privacy. Patient data obtained by companies to personalize care are not currently covered by many privacy laws. This data could be used to determine insurance premiums, benefit access, or to discriminate against individuals [9, 10]. Regulation of personalized medicines poses challenges as well. The regulatory body currently discriminates between non-personalized and personalized drugs. In addition, it requires that companies obtain a premarket approval application for a personalized device, meaning that many such devices are powered by outdated software. In contrast, personalized drugs are more readily available to patients in the absence of clear monitoring

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

guidelines. Regardless of regulation, the ethics of developing and marketing personalized medicine are difficult to parse. Balancing the need for access to care with protecting the patient or subject is tricky. Conversely, some individuals view personalized medicine as elitist or at odds with distributive justice. Individuals who may be socioeconomically unable to afford personalized medicine might miss out on the benefits of these therapies. Oncologists and oncology nurses are aware that the side effects of personalized medicine have harmful effects on those already marginalized. Thus, personalized medicine through either increased insurance costs or via the benefits of therapies may increase disparities based solely on data. Given these concerns and others, including issues surrounding informed consent, fair trade, and other ethical quandaries, the use of personalized medicine to treat the sick is unclear [11, 12]. The ethical challenges of personalized medicine are extensive. Deciding how to treat an individual should be guided by sound ethical principles of justice, equality, non-maleficence, and, most importantly, patient autonomy. Treating patients as only sources of data to predict outcomes may eventually erase a patient's autonomy if decision-making abilities are transferred to a computer or other algorithm. Respect for persons means that providers should help patients make choices, provide information about alternatives when possible, and not use patients as a means to an end. A return to paternalism would abdicate the provider of their fiduciary duty toward the patients as autonomous individuals who are best able to make healthcare choices for themselves. Meeting patient and scientific needs by ethically engaging stakeholders should be the foremost criterion in deciding the future of personalized medicine [13, 3].

Case Studies and Applications

In this section, several case studies of personalized medicine will be discussed, representing diverse areas such as oncology, pharmacogenomics, and rare diseases. These case studies exemplify a variety of approaches and methodologies used to implement personalized care. Several case studies involve patient populations seen at a comprehensive cancer center. Applications of personalized care include preventive medicine, early detection, therapy optimization for chronic health maintenance, and emergency care, with applications across all specialties. In all studied cases, interdisciplinary teams were involved in providing care, including care coordination, bioinformaticians, counseling, and consultation with medical, genetic, or other specialists, and other necessary experts. All of the following case studies are real implementations of personalized care that in the last several years have positively impacted patient outcomes [14, 15]. In all the cases described above, best efforts were taken and interdisciplinary teams were brought together to make personalized care recommendations. Personalized care is targeted and takes into account patients' goals and values, as well as considerations of symptom control and quality of life, and economic impact on the patient, healthcare provider, and society. Data were retrospectively collected and analyzed. Healthcare providers and researchers still have much to learn from past experiences of personalized medicine implementations to make progress. In addition, some cases we discussed showed the difficulty in being practical and reaching our goals. The lessons learned and ongoing challenges in each case are included in our narrative [16, 17].

Future Directions and Implications

Looking to the future, there are several intriguing possibilities for the development of personalized medicine. We envision these tools becoming even more powerful with the integration of new techniques and advancements, including genome editing tools, as well as with the guidance of advanced artificial intelligence tools for experimentation and simulation. While the path toward personalized medicine has been laid out here, the field could, and indeed should, continue to grow and change. The development of personalized medicine must continue, and our understanding of personalized strategies must continue to evolve and be refined, as our ability to engineer these custom treatments improves [18, 19]. Additionally, societies and nations around the world will need to adjust health frameworks and policies to accommodate the development and acceptance of personalized medicine. Health costs, for example, could greatly increase due to funding scientific research and providing treatments at the same time, leading to increased upfront costs and time before a return on investment. All of these developments might require a shift away from a volume-based care model, where clinics provide as many services as possible, toward a value-based model that emphasizes a holistic treatment plan with a focus on cures rather than lifelong administration. To do this, insurance policies need to shift, offering risk-sharing deals with pharmaceutical companies, and possibly moving from existing models to social health insurance funds. Finally, the futures of all these possibilities depend on the acceptance of personalized medicine by the individuals it is most likely to impact. This requires public discussion and extensive public education to ensure that mistrust, fear, or misunderstanding does not prevent effective acceptance. Further down the

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

line, pharmacogenomic research might enable therapeutic strategies for all common medications to be predicated on an individual's genetic makeup [7, 20].

CONCLUSION

Personalized medicine signifies a paradigm shift toward individualized healthcare, driven by advancements in genomics and data analytics. With capabilities for targeted disease prevention, diagnosis, and treatment, personalized medicine offers promising pathways for improved patient care. However, as it expands, the field faces challenges, particularly in maintaining ethical standards, protecting patient data, and ensuring equitable access to these innovations. Collaboration among clinicians, bioinformaticians, and policymakers is essential to address these challenges. Moving forward, personalized medicine will rely on ongoing technological advancements, supportive regulatory frameworks, and public acceptance, setting the stage for a healthcare model where treatments are not only precise but also ethically and widely accessible.

REFERENCES

1. Wang RC, Wang Z. Precision medicine: disease subtyping and tailored treatment. Cancers. 2023 Jul 28;15(15):3837.
2. Aluru KS. Precision Medicine: Leveraging AI for Personalized Patient Care. International Journal of Advanced Engineering Technologies and Innovations. 2023 Mar 25;1(02):491-516. ijaeti.com
3. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, Zhao J, Snowdon JL. Precision medicine, AI, and the future of personalized health care. Clinical and translational science. 2021 Jan;14(1):86-93. wiley.com
4. Akil AA, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. Journal of translational medicine. 2021 Apr 1;19(1):137. springer.com
5. Pavez Loriè E, Baatout S, Choukér A, Buchheim JI, Baselet B, Dello Russo C, Wotring V, Monici M, Morbidelli L, Gagliardi D, Stingl JC. The future of personalized medicine in space: from observations to countermeasures. Frontiers in bioengineering and biotechnology. 2021 Dec 13;9:739747. frontiersin.org
6. Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, Hidayat HJ, Ghafouri-Fard S, Taheri M, Jamali E. The emerging roles of NGS in clinical oncology and personalized medicine. Pathology-Research and Practice. 2022 Feb 1;230:153760. [HTML]
7. Subramanian M, Wojtusciszyn A, Favre L, Boughorbel S, Shan J, Letaief KB, Pitteloud N, Chouchane L. Precision medicine in the era of artificial intelligence: implications in chronic disease management. Journal of translational medicine. 2020 Dec;18:1-2. springer.com
8. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database. 2020;2020:baaa010.
9. Jim HS, Hoogland AI, Brownstein NC, Barata A, Dicker AP, Knoop H, Gonzalez BD, Perkins R, Rollison D, Gilbert SM, Nanda R. Innovations in research and clinical care using patient-generated health data. CA: a cancer journal for clinicians. 2020 May;70(3):182-99. wiley.com
10. Balkin JM. The fiduciary model of privacy. Harv. L. Rev. F.. 2020;134:11.
11. Wang J, Zhang Y, Aghda NH, Pillai AR, Thakkar R, Nokhodchi A, Maniruzzaman M. Emerging 3D printing technologies for drug delivery devices: Current status and future perspective. Advanced drug delivery reviews. 2021 Jul 1;174:294-316. [HTML]
12. Venigandla K. Integrating RPA with AI and ML for Enhanced Diagnostic Accuracy in Healthcare. Power System Technology. 2022 May 31;46(4).
13. Kamel Boulos MN, Zhang P. Digital twins: from personalised medicine to precision public health. Journal of personalized medicine. 2021 Jul 29;11(8):745.
14. Hamamoto R, Suvarna K, Yamada M, Kobayashi K, Shinkai N, Miyake M, Takahashi M, Jinnai S, Shimoyama R, Sakai A, Takasawa K. Application of artificial intelligence technology in oncology: Towards the establishment of precision medicine. Cancers. 2020 Nov 26;12(12):3532. mdpi.com
15. Pascual J, Attard G, Bidard FC, Curigliano G, de Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N. ESMO recommendations on the use of

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2022 Aug 1;33(8):750-68. sciencedirect.com
16. Faulkner E, Holtorf AP, Liu CY, Lin H, Biltaj E, Brixner D, Barr C, Oberg J, Shandhu G, Siebert U, Snyder SR. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group. Value in Health. 2020 May 1;23(5):529-39. sciencedirect.com
17. Grover S, Fitzpatrick A, Azim FT, Ariza-Vega P, Bellwood P, Burns J, Burton E, Fleig L, Clemson L, Hoppmann CA, Madden KM. Defining and implementing patient-centered care: An umbrella review. Patient education and counseling. 2022 Jul 1;105(7):1679-88. [HTML]
18. MacEachern SJ, Forkert ND. Machine learning for precision medicine. Genome. 2021;64(4):416-25.
19. Cammarota G, Ianiro G, Ahern A, Carbone C, Temko A, Claesson MJ, Gasbarrini A, Tortora G. Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nature reviews gastroenterology & hepatology. 2020 Oct;17(10):635-48. [HTML]
20. Libanori A, Chen G, Zhao X, Zhou Y, Chen J. Smart textiles for personalized healthcare. Nature Electronics. 2022 Mar;5(3):142-56.

CITE AS: Abdullahi Abdirahim Bashiir. (2024). Engineering Personalized Medicine: Customizing Treatments. Research Output Journal of Engineering and Scientific Research, 3(3): 23-27.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.